Tony Gershlick (@agershlick) 's Twitter Profile
Tony Gershlick

@agershlick

Jazz interventionalist specialising in coronary reconstruction

ID: 1175001451615178753

calendar_today20-09-2019 10:59:22

392 Tweet

716 Followers

37 Following

Tony Gershlick (@agershlick) 's Twitter Profile Photo

Brilliant job. Well done to all, espec research nurses, non-GCP nurses, PIs, and hard work of CTU team and Fellow @drtomkite and British Heart Foundation for their support- not forgetting the patients who trust us to do clinical trial to high research governance. Ever onwards-let's get it done!

EUROSHOCK (@euroshockstudy) 's Twitter Profile Photo

Later today, Manel Sabate IDIBAPS will present our #H2020 EURO SHOCK study at #ECMOBARNA2020 Many thanks to ECMO Barcelona for giving us the platform to spread the word about this very important project!

Tony Gershlick (@agershlick) 's Twitter Profile Photo

Thanks for this comment-the trial is testing 1 strategy but at different times therefore IF the results are +ve for v early then that will be generalizable if PCI for N-STEMI is available in that country. Also our patient population are very heterogenous within the incl criteria

Tony Gershlick (@agershlick) 's Twitter Profile Photo

Real danger is the chasing of a number (>0.95)that needs to be proven to be beneficial w/out leading to the obvious risk of complications including edge tears and sent disruption, not to mention cost. Too early to promote a number. eg ill be interest. to see if focal 0.9=hard EP

Tony Gershlick (@agershlick) 's Twitter Profile Photo

Agree of course and not advocating qualitative assessment when there is uncertainty. However your proposed "objective targets" need to be proven to be more than a randomly plucked number and should have impact ..POEM..patient oriented hard outcomes I am sure you agree

Tony Gershlick (@agershlick) 's Twitter Profile Photo

These posts have been hugely successful over the years The perfect blend of exposure to & involvement in high level CHIP PCI &TAVI with the underlying theme of evidence-based practice in a Unit that has for many years been at the cutting edge of clinical research trials. Join us

Tony Gershlick (@agershlick) 's Twitter Profile Photo

These are relevant issues to us as cardiologists working in a world where all sorts of factors (systemic&local) other than than the obvious ones impact on outcomes in ACS patients. We have a stellar cast to discuss the impact of systemic inflammatory condition on ACS. Join us !!